Johnson & Johnson just raised its full-year 2026 outlook after posting Q1 revenue of $24.1 billion — a 6.4% year-over-year increase that beat analyst estimates of $23.61 billion. Adjusted EPS came in at $2.70, nudging past the $2.68 consensus. For income investors hunting the best dividend stocks for passive income in 2026, that kind of consistent execution isn't background noise. It's the whole argument.
Best Dividend Stocks for Passive Income in 2026: Why JNJ Still Leads the Pack
Dividend investing has a reputation problem. Critics call it boring. The reality is that boring compounds. JNJ has raised its dividend for over 60 consecutive years, cementing its status as a Dividend King — a title that requires more discipline and durability than most growth stocks ever demonstrate. With the Federal Reserve's rate trajectory still uncertain heading into the second half of 2026, investors who anchored to reliable dividend payers earlier this year are looking smart right now.
JNJ's Q1 beat wasn't a fluke driven by a single blockbuster drug. It was broad-based. Guggenheim Securities senior analyst Vamil Divan, who carries a Buy rating on the stock, specifically highlighted J&J's "exciting" new product story as the engine behind its 2026 guidance confidence. That matters because the company is actively managing a well-known headwind: Stelara biosimilar competition drove Stelara sales down 61.7% year-over-year in Q1. The fact that J&J still beat revenue estimates despite that collapse tells you something important about the strength of the rest of the portfolio.
The MedTech segment and newer oncology assets — including Darzalex and Carvykti — are picking up the slack left by Stelara's erosion. This is exactly the kind of pipeline transition that separates elite dividend payers from companies that cut payouts when one product cycle ends.
JNJ Valuation and Dividend Yield: What Income Investors Are Actually Getting
Dividend investors need to think in total return terms, not just yield. JNJ's current yield sits in the 3.1–3.3% range, which isn't the highest number on a dividend screener — but yield chasing is how income investors end up holding deteriorating businesses dressed up with temporarily high payouts.
What JNJ offers instead is a combination of yield, payout safety, and capital appreciation potential. With adjusted EPS of $2.70 in Q1 alone, the annualized earnings power gives the company substantial room to maintain and grow its dividend. The payout ratio remains conservative by pharma standards, meaning dividend coverage isn't a concern even under moderate earnings pressure.
Forbes analysts flagged additional upside for JNJ stock in 2026, pointing to pipeline catalysts that aren't yet fully priced in. If the new product momentum Divan described at Guggenheim materializes through Q2 and Q3, the stock has a credible path to re-rating higher — delivering capital gains on top of the dividend income.
Track JNJ live on Stock Market ROI →
Other Top Dividend Stocks for Passive Income Worth Watching in 2026
JNJ is the anchor, but a well-constructed dividend income portfolio needs diversification across sectors. Three other names deserve consideration alongside it this year.
Realty Income (O) remains the gold standard for monthly dividend payers. As a net-lease REIT, it collects rent from recession-resistant tenants — convenience stores, pharmacies, dollar stores — and passes income directly to shareholders. In a higher-for-longer rate environment it faces valuation headwinds, but the underlying business cash flow has remained durable.
Chevron (CVX) offers exposure to energy cash flows with a dividend yield above 4% and a management team that has been explicit about shareholder return prioritization. With energy prices volatile but structurally supported through 2026, CVX serves as both an income play and an inflation hedge within a dividend portfolio.
Procter & Gamble (PG) rounds out the defensive core. Another Dividend King with over 60 years of consecutive increases, PG's pricing power in consumer staples has proven resilient through the post-pandemic inflation cycle. Organic sales growth has moderated but remained positive, and the balance sheet is fortress-grade.
The common thread across all four: these are not high-yield traps. They are businesses with durable competitive advantages, conservative payout ratios, and management teams that treat the dividend as a non-negotiable commitment.
JNJ Earnings 2026 and the Biosimilar Risk: Is Stelara's Decline Already Priced In?
The Stelara story is worth addressing directly because it will keep appearing in JNJ headlines through 2026. The 61.7% sales decline in Q1 sounds alarming in isolation. It isn't, for two reasons.
First, biosimilar erosion of Stelara was fully anticipated. J&J guided for it, analysts modeled it, and the stock absorbed the news without collapsing. Second, the company raised its full-year 2026 outlook despite that headwind — which means management has enough confidence in the rest of the portfolio to more than offset it.
The more important question is whether J&J's next-generation immunology assets can build a durable revenue bridge. Early indications from pipeline data suggest yes. Nipocalimab and other late-stage assets in the immunology and oncology pipeline represent the next phase of J&J's revenue story. If even one of those becomes a multi-billion-dollar product by 2027–2028, the Stelara chapter becomes a footnote.
For income investors specifically, none of this threatens the dividend. The payout is covered many times over by current cash generation. The Stelara decline is a growth story risk, not an income story risk.
Compare top stocks with our free screener →
Bottom Line
BUY — JNJ is the single best dividend stock for passive income entering the second half of 2026.
The Q1 beat, raised guidance, and visible new product pipeline create a setup where income investors get paid 3%+ while they wait for capital appreciation. Over the next 12 months, JNJ is positioned to reach the $175–$185 range, driven by continued top-line growth in MedTech and oncology offsetting Stelara erosion, combined with a modest multiple expansion as pipeline risk clears.
The thesis breaks if two or more late-stage pipeline assets face regulatory setbacks simultaneously, triggering an earnings reset that forces a dividend growth pause. That would undermine the core Dividend King narrative and cause institutional income funds to rotate out. Watch FDA decision dates for nipocalimab and key oncology readouts in H2 2026 as the critical checkpoints.
